Publications

June 2022
ASCO 2022 Poster Presentation

TRUST: The Efficacy and Safety of Taletrectinib in TKI-Naïve or Crizotinib-Pretreated ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) Patients (pdf)

April 2022
ELCC 2022 Poster Presentation

A Global Phase 2 Study of Taletrectinib, a Next Generation of ROS1 TKI, in ROS1 Positive Lung Cancer and Other Solid Tumors (TRUST II) (pdf)

Sept 2021
CSCO 2021 Oral Presentation

A phase II clinical study to investigate Taletrectinib (AB-106) in treating patients with ROS1 fusion positive non-small cell lung cancer (TRUST Phase II study) (pdf)

June 2021
ASCO 2021 Poster Presentation

Preliminary results from TRUST: A phase II clinical study to investigate Taletrectinib in treating patients with ROS1 fusion positive non-small cell lung cancer (NSCLC) (pdf)

October 2020
JTO Clinical and Research Reports

Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies

PMID: 34589973 PMCID: PMC8474193 DOI: 10.1016/j.jtocrr.2020.100108

September 2020
Clinical Cancer Research

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

PMID: 32591465 DOI: 10.1158/1078-0432.CCR-20-1630

August 2019
Nature Communications

The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models

PMID: 31399568 PMCID: PMC6688997 DOI: 10.1038/s41467-019-11496-z

May 2018
Oncotarget

Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study

PMID: 29805770 PMCID: PMC5955103 DOI: 10.18632/oncotarget.25263